After the success of the first edition of the Discover&Transfer program, the new students of the Biotechnology Business Institute will develop new patents from the main research institutions of Barcelona.
The fifth edition of the Biotechnology Business Institute masters began with the presentation of the course and the new educational model promoted by the Institute, Discover&Transfer. As a new addition, the students will have a new drug candidates to develop, thanks to the collaboration agreement signed with University Pompeu Fabra, promoted by UPF Ventures, and which joins the ones already established with the Bosh i Gimpera Foundation and IRB Barcelona.
During the presentation of the fifth edition, the students had a global overview of the pharmaceutical and biotechnology sector. Christian Suojanen, Co-Chairman of TTS Global Initiative and industry expert with broad experience in Life Sciences, gave a presentation on Global Business Development and gave some advice to the students on how to succeed in their professional future and how to develop their new IPs. On the other hand, the chairman of the centre, Juan R. García, dedicated his intervention to presenting the four new projects and the indication under which they will develop their drug candidates.
On this occasion, students will develop patents for breast cancer, fatty nash liver, and a cell therapy for inflammatory diseases. Students of the three specialities will work on the elaboration of the different development plans along with the technology transfer offices, from the early stage drug discovery until the treatment reaches the patient.
The collaboration agreements go beyond the formative character, and try to promote the interactions between the different scientific profiles that who ain to access the industry and academia. It is the union and commitment of the Institute with the IRB of Barcelona, the Bosch i Gimpera Foundation and University Pompeu Fabra, promoted by UPF Ventures, for the creation of new treatments in the biopharmaceutical field.